Previously, we identified that selective blockade of stromal TGFβR2 resulted in reduced metastasis, a more epithelial differentiated tumor cell phenotype, and immune changes consistent with innate immune activation (Ostapoff et al, 2014). This evidence concerns the gene TGFBR2 and neoplasm.